📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-10-14 16:36
0 analysed today
FollowTelegram
0
Today
151,853
All-time analysed
43,533
Positive
6,742
Negative
92,741
Neutral
8,769
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
4 announcements match the current filters (relevance ≥ 5).
Godavari Drugs Secures ₹34 Cr Working Capital Facility from ICICI Bank
Godavari Drugs Limited has secured board approval to avail working capital facilities aggregating up to ₹34.00 crore (₹340 million) from ICICI Bank Limited, based on a Credit Arrangement Letter dated October 12, 2026. This credit line is substantial relative to the company's size, representing approximately 30.9% of its TTM revenue (₹110 crore) and about 44.7% of its existing total debt (₹76 crore). The facility includes temporary overdraft accommodations and will require the creation of security. Managing Director Mukund Kakani was authorized to finalize and execute the documentation.
Confidence: HIGH
What changedThe board approved securing a fresh/renewed working capital limit of up to ₹34 crore from ICICI Bank Limited.
Why it mattersWorking capital access supports liquidity and ongoing pharmaceutical operations, but increased utilization may raise leverage on an already 1.0x D/E balance sheet.
Working capital limit: Rs. 340.00 MillionLimit vs TTM revenue: ~30.9%Limit vs current debt: ~44.7%Credit arrangement letter date: 12th October, 2026
📅 Short termEnsures liquidity for short-term operational requirements and procurement without immediate equity dilution.
📈 Long termLimited structural impact unless the working capital supports higher operational throughput and revenue growth without denting operating margins.
⚠ Risk flags
- High existing leverage with total debt (₹76 cr) matching net worth (D/E at 1.00)
- Increased debt drawdowns would inflate finance costs against modest operating margins (OPM ~9%)
Key Highlights
Board approved working capital limits of up to ₹340.00 Million (₹34.00 crore) from ICICI Bank
Facility sanctioned pursuant to Credit Arrangement Letter dated October 12, 2026
Limit represents ~30.9% of TTM revenue of ₹110 crore
Board authorized MD Mukund Kakani to execute facility agreements and create required security
👀 What to Watch
Track subsequent quarterly filings to see whether these credit facilities replace existing high-cost borrowings or increase overall debt beyond the current ₹76 crore, which could raise finance costs.
Godavari Drugs allots 7.86 lakh shares to Promoters; raises Rs 5.25 Cr via warrant conversion
Godavari Drugs has allotted 7,86,690 equity shares to its promoter group following the conversion of warrants issued in early 2026. The company received Rs 5.25 crore, representing the final 75% payment of the Rs 89 per share issue price. This conversion results in a 7.77% equity dilution for existing shareholders. Additionally, 15,73,375 warrants remain outstanding, which could lead to further dilution within the 18-month conversion window.
Confidence: HIGH
What changedThe company converted 7.86 lakh promoter warrants into equity shares, increasing the total share count and bringing in Rs 5.25 crore in cash.
Why it mattersThis infusion of capital strengthens the balance sheet of a small-cap firm with a 1.0 Debt-to-Equity ratio. Promoter participation at Rs 89 per share signals confidence in the business despite recent price volatility.
Amount raised (this tranche): Rs 5.25 CrConversion Price: Rs 89Equity Dilution (this tranche): 7.77%Remaining Warrants: 15,73,375Fundraise vs Net Worth: ~6.9%
📅 Short termThe news is likely to be viewed positively as it confirms promoter commitment and provides immediate liquidity.
📈 Long termThe structural impact depends on the conversion of the remaining warrants and the company's ability to improve its 7% ROCE using the fresh capital.
⚠ Risk flags
- Equity dilution of 7.77% in this tranche
- Potential for further ~14% dilution from remaining warrants
Key Highlights
Allotment of 7,86,690 equity shares to 9 promoter-group individuals at Rs 89 per share.
Receipt of Rs 5.25 crore as the final 75% subscription amount for the converted warrants.
Paid-up equity capital increased from Rs 10.13 crore to Rs 10.91 crore.
15,73,375 warrants remain outstanding for future conversion into equity shares.
The conversion price of Rs 89 is at a ~12.7% discount to the current market price of Rs 102.
👀 What to Watch
Investors should monitor the utilization of the newly raised capital, particularly if it is used to reduce the company's Rs 76 crore debt, and track the timeline for the conversion of the remaining 15.73 lakh warrants.
Godavari Drugs Q1 FY27: Revenue Up 17.4% YoY to ₹27.96 Cr, PAT Rises to ₹1.11 Cr
Godavari Drugs reported a 17.4% YoY increase in revenue to ₹27.96 Cr for the quarter ended June 30, 2026. Net profit grew 6.7% YoY to ₹1.11 Cr, although it saw a sequential decline of 14% from the March 2026 quarter (₹1.29 Cr). Notably, EPS decreased to ₹1.10 from ₹1.38 in the year-ago period due to an increase in paid-up equity capital from ₹7.53 Cr to ₹10.13 Cr. The company continues to operate with tight margins, with total expenses accounting for 96% of total revenue.
Confidence: HIGH
What changedThe company has reported its Q1 FY27 results, showing steady YoY revenue growth but a sequential slowdown compared to Q4 FY26.
Why it mattersFor a micro-cap company with a market cap of ₹84 Cr and a D/E ratio of 1.0, maintaining profitability while managing interest costs (₹0.90 Cr this quarter) is critical for financial stability.
Revenue (Q1 FY27): ₹27.96 CrNet Profit (Q1 FY27): ₹1.11 CrYoY Revenue Growth: 17.4%QoQ Revenue Growth: -15.7%Equity Capital: ₹10.13 Cr
📅 Short termThe stock may remain range-bound as the YoY growth is tempered by a sequential decline in both revenue and profit.
📈 Long termLimited structural change; the company needs to demonstrate significant margin expansion or debt reduction to re-rate from its current P/E of 20.4.
⚠ Risk flags
- High debt-to-equity ratio (1.0)
- EPS dilution due to increased share capital
- Low operating margins
Key Highlights
Revenue from operations increased 17.4% YoY to ₹27.96 Cr from ₹23.81 Cr.
Net profit for the quarter stood at ₹1.11 Cr, up from ₹1.04 Cr in June 2025.
Paid-up equity share capital rose to ₹10.13 Cr from ₹7.53 Cr YoY, leading to EPS dilution.
Finance costs decreased slightly to ₹0.90 Cr compared to ₹1.00 Cr in the same quarter last year.
Total expenses rose to ₹26.93 Cr, driven largely by cost of materials consumed at ₹26.15 Cr.
👀 What to Watch
Investors should monitor if the company can translate its increased capital base into higher operating margins, as the current ROCE of 7% remains low relative to the cost of debt.
Godavari Drugs Q1 Net Profit Up 6.7% to ₹1.11 Cr; Promoters Infuse ₹5.25 Cr via Warrant Conversion
Godavari Drugs reported a 17.4% YoY increase in revenue to ₹27.96 Cr for Q1 FY27. Net profit grew marginally by 6.7% to ₹1.11 Cr, while EPS stood at ₹1.10, impacted by a larger equity base. Simultaneously, the company allotted 7,86,690 equity shares to promoters following the conversion of warrants at ₹89 per share, bringing in ₹5.25 Cr in fresh capital (the final 75% payment). This infusion is notable for a micro-cap company with a market capitalization of ₹84 Cr.
Confidence: HIGH
What changedThe company reported its Q1 FY27 financial results and completed a promoter-led fundraise through the conversion of warrants into equity shares.
Why it mattersThe promoter infusion of ₹5.25 Cr represents approximately 6.25% of the company's market cap, signaling promoter confidence. However, the company continues to operate with low margins and a relatively high debt load for its size.
Revenue Growth (YoY): 17.4%Net Profit (Q1 FY27): ₹1.11 CrWarrant Conversion Price: ₹89Fresh Capital Infused: ₹5.25 CrFundraise vs Market Cap: ~6.25%
📅 Short termThe stock may see positive sentiment due to the promoter's capital infusion and steady revenue growth, though the marginal profit growth and equity dilution are limiting factors.
📈 Long termStructural growth depends on the company's ability to scale its pharmaceutical operations and improve its ROCE, which currently stands at a modest 7%.
⚠ Risk flags
- High Debt-to-Equity ratio (1.0)
- Low operating margins (~10%)
- Equity dilution from warrant conversion
Key Highlights
Revenue from operations increased 17.4% YoY to ₹27.96 Cr from ₹23.81 Cr.
Net profit for the quarter rose to ₹1.11 Cr compared to ₹1.04 Cr in the same quarter last year.
Allotted 7,86,690 equity shares to promoters at an issue price of ₹89 per share.
Received ₹5.25 Cr as the final 75% balance payment for the warrant conversion.
Paid-up equity share capital increased from ₹10.13 Cr to ₹10.91 Cr following the allotment.
👀 What to Watch
Investors should monitor if the ₹5.25 Cr capital infusion is used to reduce the company's high debt (D/E of 1.0) or for working capital. Watch for improvements in operating margins, which remain tight at approximately 10%.
